Trevena

TRVN75

Penny Stock

$4.89arrow_drop_down1.21%-$0.06

Penny Stock

TRVN75

$4.89

arrow_drop_down1.21%-$0.06

Penny Stock

Performance History

Key Stats
Open	$5.20
Prev. Close	$4.45
EPS	-56.50
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$5.07M
PE Ratio	-

	LOW	HIGH
Day Range	4.73	5.29
52 Week Range	3.35	25.75

Ratios







EPS	-56.50

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Trevena (TRVN)

Trevena Inc (TRVN) is a pharmaceutical company that focuses on developing and commercializing new treatment options for patients suffering from various diseases. The company's stock price history shows fluctuations over the years, with both ups and downs. However, it is important to consider the overall performance of the company in the market before making any investment decisions.

When looking at the stock's current quote, investors can see the latest market price for Trevena Inc (TRVN). This information provides a snapshot of how the stock is performing at a given moment. It is important to note that stock prices are subject to change throughout the trading day, so investors should stay updated with the latest information.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Ms. Carrie L. Bourdow
Headquarters: Chesterbrook
Employees: 35
Exchange: NASDAQ

Keep an eye on Trevena

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Trevena 's (TRVN) price per share?

The current price per share for Trevena (TRVN) is $4.89. The stock has seen a price change of -$0.06 recently, indicating a -1.21% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Trevena (TRVN)?

For Trevena (TRVN), the 52-week high is $25.75, which is 426.58% from the current price. The 52-week low is $3.35, the current price is 45.97% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Trevena (TRVN) a growth stock?

Trevena (TRVN) has shown an average price growth of 0.41% over the past three years. It has received a score of -2 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Trevena as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Trevena (TRVN) stock price performance year to date (YTD)?

As of the latest data, Trevena (TRVN) has a year-to-date price change of -73.53%. Over the past month, the stock has experienced a price change of 2.52%. Over the last three months, the change has been -50.17%. Over the past six months, the figure is -64.44%. Looking at a longer horizon, the five-year price change stands at -99.21%.

help

Is Trevena (TRVN) a profitable company?

Trevena (TRVN) has a net income of -$40.29M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 17.98% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -2K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $3.12M, although specific revenue growth data is currently not available. The gross profit is $562K. Operating income is noted at -$35.29M. Furthermore, the EBITDA is -$35.01M.

help

What is the market capitalization of Trevena (TRVN)?

Trevena (TRVN) has a market capitalization of $4.22M. The average daily trading volume is 108.07K, indicating the stock's liquidity and investor engagement.

News

Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models

HEALTH

6/20/2024

Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models